The GPC3-specific humanized monoclonal IgG1 GC33 (a.k.a. codrituzumab) has previously demonstrated excellent preclinical and clinical localization to HCC-expressing GPC3 in vivo [5,13]. Here, GPC3 is linked to hepatocellular carcinoma.